Sanofi, Formation Bio and OpenAI Forge First-in-class AI Collaboration
In a forward-thinking move, Sanofi, Formation Bio, and OpenAI have joined forces to harness the power of artificial intelligence in
Read more
Latest
Celltrion’s Omlyclo Gets EC Green Light for Allergic Conditions
The approval is supported by robust clinical evidence, including results from a global Phase III trial. Omlyclo® is the first
Read more
Takeda Inks $2.2 Billion License Deal for AC Immune’s Alzheimer’s Immunotherapy
Takeda has secured an exclusive global option and license agreement for AC Immune’s promising active immunotherapy targeting amyloid beta for
Read more
Boehringer and Walgreens Partner to Improve Diversity in Clinical Trials
In this partnership, Boehringer Ingelheim will utilise specific US-based pharmacy store chain Walgreens sites for clinical trials focusing on individuals
Read more
BMS and Cellares Enter $380m CAR T Cell Therapy Capacity & Supply Deal
Bristol Myers Squibb (BMS) announced on Monday it has entered a worldwide capacity reservation and supply agreement with the California-headquartered Integrated
Read more
NIH Researchers Improve Cancer Drug Response Prediction Using scRNA-seq Data AI Model
In a proof-of-concept study, researchers at the National Institutes of Health (NIH) explored the feasibility of employing transfer learning, a machine
Read more
Ventus’ NLRP3 Inhibitor Shows Potential for CNS Diseases in Phase 1 Trial
Ventus Therapeutics, a US-based clinical-stage biopharmaceutical company leveraging its exclusive structural biology and computational chemistry platform, ReSOLVE™, has disclosed promising
Read more
Nutcracker’s mRNA Drug Candidate for Prostate Cancer Effectively Targets CD3 T cells
Preclinical data shows that Nutcracker’s mRNA drug candidate NTX-470 effectively targets CD3 T cells, demonstrating selective engagement with minimal unintended
Read more
Vertex Expands Immunotherapy Capabilities with $4.9bn Alpine Acquisition
Vertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc., a biotechnology firm dedicated to pioneering protein-based immunotherapies, jointly announced the signing
Read more
Pfizer’s ABRYSVO® Shows Promising Results in Phase 3 Trial Targeting RSV Prevention in High-Risk Adults
Pfizer has announced encouraging findings from its ongoing pivotal Phase 3 clinical trial, known as MONeT (RSV IMmunizatiON Study for
Read more